What can I say...., page-7

Go figure......

The company has $17.6m in debt.

Cash at the end of September was $9.4m

Net cash was there fore negative $8.2m.

BNO will bill burn another $3m in the next quarter.

The company has a market capitalisation of $50m.

The "enterprise value" is therefore $58.2m

If BNO was an explorer, its cash burn rate and net debt position would have investors rushing the exits.

Does anyone seriously believe that there is not going to be a capital raising?

How do investors think that this company is actually going to pay for the mooted BNC 210 clinical trial?

I agree with Bioshares - avoid.

....but you knew that.

Good luck holders.

Cheers,
DDD